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Introduction 
Colorectal cancer is one of the leading cancers in the
western countries with half a million deaths worldwide
every year [1]. At diagnosis almost a third of all patients
already have metastatic disease and nearly 50% of all
diagnosed colorectal cancer patients will subsequently
develop metastases with often fatal prognosis [2].
Molecular markers of solid tumors can not only be use-
ful in cancer classification but they can also predict dis-
semination of the disease [3]. So far, no perfect molecu-
lar marker has been found to predict disease progression. 
Tumor growth and spread are absolutely dependent
on their ability to induce angiogenesis [4] with vascular
endothelial growth factor (VEGF) as the most important
cytokine involved in the process [5]. VEGF plays an
important role in progression, invasion and spread of
colorectal cancer by influencing proliferation and
migration of endothelial cells [6]. It has also been
reported to be a useful marker of prognosis by signifi-
cantly correlating with angiolymphatic invasion, lymph
node status and depth of invasion, although it was not an
independent prognostic factor [7]. 
Total VEGF is not a sufficient diagnostic tool in
patients with colorectal cancer because of poor sensi-
tivity (36%) [8]. The ligands of the VEGF family
include VEGF-A, VEGF-B, VEGF-C, VEGF-D and
VEGF-E [9]. VEGF-A is the most abundantly
expressed in colorectal cancer tissues and therefore
seems to be of greater value then total VEGF [5]. 
One of the recently emerging cytokines associated
with angiogenesis is endoglin [10]. Endoglin, also
known as CD105, is a trans-membrane co-receptor for
TGF-β1 and TGF-β3. It modulates the cell response to
those mediators. Biochemically it is a 180 kDa glyco-
protein. Beside angiogenesis it plays a role in
hematopoiesis and cardiovascular system development
[11]. CD105 is induced by hypoxia. As it is present
mainly in new vessels, endoglin proved to be very use-
ful in assessment of newly formed vessels in malignant
neoplasms [12]. Antibodies raised against endoglin
were also used for tumor imaging [10,13]. Intra-tumor
microvessel density determined by immunohistochem-
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ical staining for endoglin has been reported to be an indi-
cator of poor prognosis in many types of solid neoplasia
such as: breast carcinoma, cervical cancer, endometrial
carcinoma, gastric carcinoma, melanoma, some testicu-
lar tumors, non-small cell lung cancer, prostate cancer,
renal cell carcinoma and squamous cell carcinoma [14].
Many reports indicate that endoglin assessed
immunohistochemically in colorectal cancer correlates
not only with tumor microvessel density, but also with
survival [7,15]. It has been also reported as a valuable
parameter predicting patients having an increased risk
of developing metastatic disease [16]. It correlates
with tissue expression of VEGF [17]. 
Endoglin is not only expressed on cell surface since
its soluble form can also be detected in blood. Soluble
endoglin was shown to be increased in many tumors
including: myeloid malignancies and breast cancer [18].
Two studies also documented elevated levels of circu-
lating endoglin in colorectal cancer patients [15,19].
Both used local immunoassays for its detection. 
The aim of our study was to assess the efficacy of
plasma endoglin when compared with VEGF-A, as a
marker of tumor spread and distant metastases in col-
orectal cancer patients. 
Materials and methods
Tissue samples. This study was performed on plasma samples
from 48 patients with colorectal cancer treated in the II Department
of General and Gastroenterological Surgery, Medical University of
Bialystok. Control group consisted of 22 healthy subjects. 
Among the colorectal cancer patients there were 25 men and
23 women (Table 1). The mean age was 65.2 (32 to 83). The can-
cer was localized in rectum in 27 patients, in sigmoid colon in 8, in
cecum in 5, in ascending colon in 4, in descending colon in 1 and
in transverse colon in 3 patients. 29 patients underwent curative
resection and 19 patients – palliative resection. In all cases patho-
logic examination indicated adenocarcinoma. According to Dukes'
classification, 6 patients were at stage A, 12 at stage B, 16 at stage
C and 14 at stage D. In all colorectal cancer patients blood samples
were collected before surgery and at post-operative days 3 and 10. 
The control group comprised 11 men and 11 women, aged 32
to 78 (mean 64.9). They were healthy subjects. Patients and volun-
teers with clinical or laboratory signs of infection were excluded
from the study. Exclusion criteria for control subjects also com-
prised malignancy, liver and kidney diseases, chronic connective
tissue and skin diseases. Ethics committee approval and informed
consent from all patients were obtained.
Blood samples from patients with colorectal cancer were
obtained prior to any treatment. After an overnight fast, 4.5 ml of
venous blood were poured into a tube containing 0.5 ml EDTA.
Immediately after sampling, specimens were centrifuged at 1000 rpm
for 15 minutes in 4°C. The supernatant – platelet poor plasma was
transferred to Eppendorf's tube and frozen at –70°C until analysis. 
VEGF-A was determined according to George et al. [20] and
endoglin – using a commercially available ELISA kit purchased
from Research Diagnostics Inc., USA.
Statistical analysis. Data were analyzed using Statistica 5.1. com-
puter software (StatSoft Inc, Tulsa). Normality of variable distri-
bution was tested using Shapiro-Wilk W test. The normally dis-
tributed data were expressed as mean ± SEM. The non-Gaussian
data were presented as median (quartile range). Non-normally dis-
tributed variables were log-transformed prior to regression analy-
sis. ANOVA was employed to test differences between groups. The
Mann-Whitney test or Student´s t test were used in statistical
analysis to compare differences between individual groups. For
differences between assessments performed on days 0, 3 or 10
dependent t-Student test or Wilcoxon test were used. Correlations
were determined using Spearman's analysis. A two-tailed p value
<0.05 was considered to be statistically significant.
Results
We found significant increases in VEGF-A concentra-
tions in plasma of patients with colorectal cancer in
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Table 1. Clinical and pathological characteristics of the colorectal
cancer patients.
Dukes' stage C (p<0.05) and D (p<0.01) (Fig. 1), when
compared to the control group. Mean levels of plasma
VEGF-A in all colorectal cancer patients combined
were also greater than in healthy subjects (p<0.01)
(Fig. 3). Operation did not change VEGF-A level sig-
nificantly in colorectal cancer patients (Fig. 3). The
levels of VEGF-A postoperatively were still greater in
cancer groups than in the control group both on day 3
(p<0.01) and 10 (p<0.05), with no significant differ-
ence between the days. 
Endoglin was detectable in plasma of 91.7% of the
operated patients and in 86.4% of the normal controls.
The levels of endoglin obtained with the commercial
ELISA kit were greater than those reported by Li [16],
who used an indirect sandwich ELISA kit. At the same
time they were about 8-fold lower than those reported
in serum [31]. In contrast to VEGF-A, no significant
difference in plasma endoglin was found preoperative-
ly between colorectal cancer patients and healthy vol-
unteers (Fig. 4).
When analyzing disease staging according to Dukes,
there was an apparent gradual rise in endoglin level from
groups A to D with a significant difference between
group D and healthy subjects (p<0.01) (Fig. 2). Endoglin
levels in the group D were greater than in groups A, B or
C (p<0.05). This was also reflected in the significantly
greater value of endoglin in metastasis-positive (Dukes
D) compared with metastasis-negative patients (Dukes
A, B and C combined) (p<0.01) (data not shown).
As shown in Fig. 6, after the operation endoglin
levels initially (on postoperative day 3) decreased sub-
stantially when compared with preoperative concen-
trations (p<0.001), then they rose at postoperative day
10 to reach greater values than on postoperative day 3
(p<0.001). They remained lower than preoperatively
(p<0.001). The endoglin concentrations, assessed post-
operatively at day 3 were significantly lower than
those in healthy subjects (p<0.01).
When analyzing relationship between laboratory
and clinical parameters of colorectal cancer patients,
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Fig. 1. Preoperative concentration of VEGF-A in plasma of normal
controls (control) and patients with colorectal cancer at stages A-
D according to Dukes. (Results are given as median ± quartile
range. Significant differences of Mann-Whitney U test are marked
with *- p<0.05 or **- p<0.01. 
Fig. 2. Preoperative concentration of endoglin in plasma of normal
controls (control) and patients with colorectal cancer at stages A-
D according to Dukes. (Results are given as mean ± SEM. Signif-
icant differences are marked with *- p<0.05 or **- p<0.01. 
Fig. 3. Influence of operation on the concentration of VEGF-A in
plasma of patients with colorectal cancer. For comparison the con-
trol values are also shown (control). (Results are given as median
+/- quartile range. Differences significant according to Mann-
Whitney U test are marked as: * – p<0.05; ** – p<0.01. No sig-
nificant differences between days 0, 3 or 10 were found).
Fig. 4. Influence of operation on the concentration of endoglin in
plasma of patients with colorectal cancer. For comparison the con-
trol values are also shown (control). (Results are given as median
+/- quartile range. Differences significant according to Mann-
Whitney U test are marked as: **- p<0.01; ***- p<0.001)
we found a strong positive correlation between VEGF-
A levels, as assessed on day 10, and postoperative CA
19-9 (Table 2). Incidence of distant metastases was
significantly greater with increased VEGF-A as
assessed postoperatively both on day 3 and day 10, as
we demonstrated using Mann-Whitney U test (p<0.05)
(data not shown). However, the preoperative VEGF-A
values showed no significant difference between
metastases-negative and -positive patients. Using the
Spearman's test we found a moderate positive correla-
tion (R=0.43) between plasma concentration of
VEGF-A and endoglin in patients with colorectal can-
cer (p<0.05).
Endoglin concentrations in plasma correlated posi-
tively with several indices of colorectal cancer stage.
We found a moderate association between endoglin
concentrations in plasma and Dukes stage, independ-
ently of the day of endoglin assessment (Table 2). Sim-
ilarly, there was a correlation between endoglin and
CEA as well as CA19.9 level in serum. 
Discussion
We present for the first time results of plasma endoglin
assessment in colorectal cancer patients using com-
mercially available ELISA test. Although endoglin
levels were not greater in colorectal cancer patients
than in healthy control, they were strongly associated
with distant metastases. In patients with metastases
(stage D according to Dukes) endoglin had markedly
elevated values not only when compared to the control
group, but also to all other subgroups of colorectal
cancer patients (Fig. 2).
Angiogenesis is a key process in colorectal cancer
growth, invasion and dissemination. Among numerous
cytokines involved in new vessel formation, VEGF
has been among the best characterized [21]. Of the
whole VEGF family, VEGF-A seems to be the most
important for colorectal cancer spread [22]. Indeed,
VEGF-A expression enhancement has been previously
demonstrated in colorectal cancer patients as com-
pared to normal controls. An association of VEGF-A
tissue expression with tumour grade and size was also
reported [5]. It was also shown that VEGF-A mRNA
expression in colorectal mucosa strongly correlates
with liver metastases and that VEGF-A concentrations
in serum are an independent predicting factor for sur-
vival in patients with colorectal cancer [23]. 
Our results confirm a significant correlation
between VEGF-A and clinical stages of colorectal can-
cer. We demonstrated increases in plasma cytokine
levels of patients when compared with healthy sub-
jects. We also found a strong positive association of
VEGF-A plasma concentrations assessed postopera-
tively and the presence of distant metastases. This was
in line with postoperative CA19.9 values. We observed
a moderate unsignificant increase in VEGF-A plasma
levels following the operation performed in colorectal
cancer patients. This might be the result of thrombo-
cytes and neutrophils breakdowns, containing substan-
tial amounts of VEGF, as a result of surgical manipu-
lations [24].
Endoglin, a hypoxia-induced membrane glycopro-
tein [25], is part of the TGF-β receptor complex; it can
modulate cellular responses to TGF-β implicated in
the early steps of angiogenesis [26]. Endoglin modu-
lates endothelial-mesenchymal signaling and enhances
cell proliferation [14]. Normal levels of endoglin are
mandatory for physiologic angiogenic activity [27].
Endoglin knockout mice died of defective vascular
development during early gestation [28]. Endoglin
gene mutations are associated with hereditary hemor-
rhagic teleangiectasia type 1, characterized by arterio-
venous malformations and bleedings [14].
It has been shown that endoglin expression corre-
lates with tumor infiltration, occurrence of metastases
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Table 2. Chosen correlations between pathological or laboratory parameters and concentrations of VEGF-A and endoglin in patients with
colorectal cancer. 
and nodal involvement, but not with tumor site or
degree of differentiation. The number of endoglin-pos-
itive vessels was significantly associated with a
decreased rate of overall survival [16]. 
In contrast to VEGF-A, we did not find any signif-
icant difference in plasma endoglin between colorectal
cancer patients, as assessed preoperatively, and healthy
volunteers (Fig. 4). This is in line with findings by
Takahashi et al. [19]. At the same time we observed
association of plasma endoglin with stage of malig-
nancy. We demonstrated an apparent gradual rise in
endoglin with advancing Dukes' stages. Our results
confirm the increased level of endoglin in plasma of
patients with metastatic colorectal cancer (Figs. 2, 3).
Endoglin was also associated with other parameters
such as: CEA and CA19.9 in serum (Table 2). Thus
endoglin seems to be a valuable marker of colorectal
cancer invasion and spread.
Soluble endoglin has been reported to rise in plas-
ma of breast cancer patients who developed metastases
as compared to both normal controls and cancer
patients without distant spread [29]. Elevated serum
endoglin was associated with distant metastases not
only in breast, but also in colorectal cancer and in other
solid tumors [19]. Also Li et al. [15] using an indirect
sandwich ELISA described a correlation between plas-
ma endoglin and Dukes' stages. 
Surgical treatment of colorectal cancer resulted in
decreased endoglin concentrations as assessed at day 3
and then their rise at day 10 (Fig. 4). The postoperative
endoglin levels still correlated with clinical stage. The
explanation of endoglin decrease after the operation in
colorectal cancer patients might be at least in part due
to pro-inflammatory cytokines, such as tumour necro-
sis factor α action. TNF-α has been reported to down-
regulate endoglin at post-transcriptional level [15]. Li
et al. [15] did not find significant difference between
pre- and postoperative samples from 14 colorectal can-
cer patients, suggesting that postoperative angiogene-
sis during the process of wound healing is likely to
overshadow a lowered endoglin level following
removal of the tumour. 
We have found a significant correlation between
plasma VEGF-A and endoglin in colorectal cancer
patients (R=0.043, p<0.05). So far, VEGF-A has been
regarded as one of the most important angiogenic
cytokines in colorectal cancer. However, based on our
results, it was endoglin that showed stronger associa-
tion with distant metastases. We suggest that endoglin
might be a better marker for assessing cancer stage and
especially in selecting patients at risk of developing
metastatic disease.
Does endoglin offer anything more than a diagnos-
tic tool for colorectal cancer patients? In metastatic
colorectal cancer antiangiogenesis drugs have been
claimed a promising modality of treatment [30]. Anti-
VEGF-A humanized mouse monoclonal antibody
(bevacizumab) in addition to chemotherapy has been
reported to improve survival of patients with previous-
ly untreated metastatic colorectal cancer [31]. Howev-
er, bevacizumab used in combination with Irinotecan,
fluorouracil or leucovorin for the treatment of metasta-
tic colorectal cancer has many side effects. The com-
mon ones include hypertension, proteinuria, bleeding
and impaired wound healing. Infrequently life-threat-
ening complications have been reported, such as arte-
rial thrombosis, gastrointestinal perforation and
reversible focal posterior leukoencephalopathy [32].
Endoglin as a cell-surface glycoprotein of newly
formed microvessels is another promising target for
antiangiogenic therapy, especially in cancer patients at
risk of developing metastases [12]. Different in vitro
and in vivo studies have demonstrated that anti-
endoglin monoclonal antibodies induced long-lasting
suppression of tumor growth and metastasis in differ-
ent human and murine tumor models [13]. Preliminary
experimental data confirmed high efficacy of anti-
endoglin treatment without severe toxicity [33]. A
monoclonal antibody against endoglin linked to ricin-
A is presently in preclinical phase [34].
To summarize, we showed that endoglin assess-
ment in plasma does not seem useful as a maker of col-
orectal cancer. Our observations indicate, however,
that it might be helpful in selecting patients with
metastatic disease. We suggest that patients with high
values of endoglin, as well as VEGF-A should be
scanned for metastases. 
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